ASCO GU 2018: Utilization and Outcomes of Chemoprophylaxis for the Prevention of Venous Thromboembolism Following Radical Cystectomy: A Population-Based Study
Methods:
Using the Premier Hospital Database (Premier, Inc., Charlotte, NC), the authors retrospectively identified patients who underwent RC for bladder cancer in the US between 2006 and 2015. Administration of chemoprophylaxis within 24 hours of surgery was deemed consistent with recommendations. A subgroup analysis of higher volume hospitals ( a minimum of 10 RCs annually) compared outcomes of DVT, PE, and bleeding between patients in hospitals with uniform use versus no use of chemoprophylaxis. Multivariable analysis was used to evaluate predictors of under-utilization of chemoprophylaxis.
Results:
Among the cohort of 9,133 patients (48,714 patients after weighting adjustment) undergoing RC, 35.1% were administered recommended chemoprophylaxis, with an increase in utilization from 20.7% in 2006 to 49.6% in 2015. Characteristics associated with decreased likelihood of chemoprophylaxis administration included patient age ≥65 years, Charlson Comorbidity Index score ≥2, rural hospital location, commercial insurance, and year of surgery prior to 2010. Patients who received recommended chemoprophylaxis had significantly lower rates of VTE (5.1% vs 6.0%) and PE (2.0% vs 3.1%), but elevated rates of bleeding (12.8% vs 7.7%).
Conclusions:
The authors conclude that greater compliance with the recommended use of chemoprophylaxis following RC may be associated with a decreased risk of PE and VTE, but also with increased risk of bleeding.
Presented by: Stephen Reese, Harvard Medical School, Boston, MA, USA
Co Authors: Matthew Mossanen, Dimitar V. Zlatev, Daniel Pucheril, Benjamin I. Chung, Steven Lee Chang; Brigham and Women's Hospital, Boston, MA; Brigham and Women’s Hospital, Boston, MA; Massachusetts General Hospital/ Harvard Medical School, Boston, MA; Stanford University School of Medicine, Stanford, CA
Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre @GoldbergHanan at the 2018 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, February 8-10, 2018 - San Francisco, CA